Perspective Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
AMEX
Perspective Therapeutics Director Maria E Martinez was granted 50,000 stock options as part of her 2026 annual equity award.
AMEX
Perspective Therapeutics Director Frank Morich was granted 50,000 stock options as his 2026 annual equity award, exercisable at $5.35 per share.
AMEX
Perspective Therapeutics Director Robert F. Williamson III received an annual equity award of 50,000 stock options, vesting in March 2027.
AMEX
Perspective Therapeutics Director Heidi Henson was granted 50,000 stock options as her 2026 annual equity award, vesting fully on March 2, 2027.
AMEX
Perspective Therapeutics Director Lori A. Woods was granted 50,000 stock options as her 2026 annual equity award.
AMEX
Perspective Therapeutics, Inc. CEO Johan M. Spoor received an annual equity award of 735,000 stock options with an exercise price of $5.35, vesting over four years.
AMEX
Perspective Therapeutics' Chief Accounting Officer, Jonathan Hunt, was granted 90,000 stock options as his 2026 annual equity award.
AMEX
Perspective Therapeutics' Chief Medical Officer, Markus Puhlmann, was granted 150,000 stock options as part of his 2026 annual equity award.
AMEX
Perspective Therapeutics' Chief Accounting Officer, Jonathan Hunt, acquired 11,000 shares of common stock, increasing his beneficial ownership.
AMEX
A director at Perspective Therapeutics, Inc. has increased their indirect beneficial ownership of common stock through a recent purchase.
AMEX
Perspective Therapeutics' CFO, Joel Sendek, was granted 600,000 stock options with an exercise price of $3.54, vesting over four years.
AMEX
Perspective Therapeutics Director Maria E Martinez was granted 75,000 stock options with an exercise price of $3.38, vesting over three years.
AMEX
CEO Johan Spoor recently purchased additional shares of Perspective Therapeutics, increasing his direct and indirect holdings in the company.
AMEX
Director Robert F. Williamson III increases his holdings in Perspective Therapeutics through recent stock purchases.
AMEX
Juan Graham, CFO of Perspective Therapeutics, recently purchased 33,333 shares of the company's common stock at an average price of $2.2484 per share.
AMEX
Director Lori A. Woods reports purchasing 23,475 shares of Perspective Therapeutics at $2.1299 per share, increasing her indirect holdings.
AMEX
Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics, received a grant of 165,000 stock options as part of his annual equity award for 2025.
AMEX
Jonathan Robert Hunt, Chief Accounting Officer of Perspective Therapeutics, Inc., was granted stock options for 75,000 shares on March 3, 2025.
AMEX
Johan M. Spoor, CEO of Perspective Therapeutics, Inc., was granted stock options to purchase 650,000 shares of common stock on March 3, 2025, as part of his annual equity award.
AMEX
Director Heidi Henson acquired 50,000 stock options in Perspective Therapeutics, Inc. as part of her annual equity award.
AMEX
Robert F. Williamson III, a director at Perspective Therapeutics, Inc., was granted a stock option to purchase 50,000 shares of common stock.
AMEX
Director Frank Morich received a grant of 50,000 stock options in Perspective Therapeutics, Inc.
AMEX
Director Lori A. Woods receives stock options as part of her annual equity award.
AMEX
Juan Graham, CFO of Perspective Therapeutics, Inc., reports the acquisition of stock options.
AMEX
Director Heidi Henson acquired 25,975 shares of Perspective Therapeutics common stock through a revocable trust at a price of $3.85 per share.
AMEX
Perspective Therapeutics CEO, Johan M. Spoor, purchased 8,000 shares of common stock at a weighted average price of $3.7665 on December 4, 2024.
AMEX
A director of Perspective Therapeutics, Inc. has amended a previous filing to correct reported beneficial ownership figures following a 1-for-10 reverse stock split.
AMEX
Perspective Therapeutics CEO Johan Spoor files an amended Form 4 to correct previously reported stock ownership figures, adjusting for a reverse stock split.
AMEX
Robert F. Williamson III, a director at Perspective Therapeutics, Inc., purchased 6,266 shares of common stock in the open market on November 25, 2024.
AMEX
Perspective Therapeutics' Chief Financial Officer, Jonathan Hunt, has acquired additional shares of the company's common stock through a series of transactions on November 25, 2024.